<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02108704</url>
  </required_header>
  <id_info>
    <org_study_id>HPPD</org_study_id>
    <nct_id>NCT02108704</nct_id>
  </id_info>
  <brief_title>Helicobacter Pylori Eradication Study in Parkinson's Disease</brief_title>
  <official_title>Helicobacter Pylori Eradication in Parkinson's Disease: A Double-blind Randomised Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Malaya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Malaya</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has been hypothesized, based on epidemiological observations, that Helicobacter pylori
      (HP) infection may play a role in the pathogenesis of Parkinson's Disease (PD). Previous
      studies have also shown that HP eradication therapy may result in improvements in levodopa
      pharmacokinetics and motor fluctuations. This study aims to examine the effects of HP
      eradication, using a double-blind randomized placebo-controlled trial design in a relatively
      large cohort of patients. Outcomes of interest include motor function, gastrointestinal
      symptoms and health-related quality of life. The investigators hypothesize that HP
      eradication will lead to improvements in motor function. The primary outcome of interest is
      the &quot;ON&quot;-medication Unified PD Rating Scale (UPDRS) Part III score at 3 months. Secondary
      outcomes include Purdue Pegboard Score, Timed Test of Gait, Dyskinesia and Bradykinesia
      scores measured by Parkinson's Kinetigraph (PKG), 72 hour Diary, Leeds Dyspepsia
      Questionnaire (LDQ), Parkinson's Disease Questionnaire (PDQ-39), UPDRS Part I, Part II and
      Part IV; and Montreal Cognitive Assessment (MOCA).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>&quot;On-medication&quot; UPDRS Part III score</measure>
    <time_frame>at 3 months after randomisation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>&quot;On-medication&quot; Pegboard Score</measure>
    <time_frame>at 3 months after randomisation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>&quot;On-medication&quot; Timed Gait Score</measure>
    <time_frame>at 3 months after randomisation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>&quot;On-medication&quot; UPDRS Part III score</measure>
    <time_frame>at 1 year post randomisation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>&quot;On-medication&quot; Pegboard Score</measure>
    <time_frame>at 1 year post randomisation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>&quot;On-medication&quot; Timed Gait Score</measure>
    <time_frame>at 1 year post randomisation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parkinson's Kinetigraph (PKG) Bradykinesia and Dyskinesia Scores</measure>
    <time_frame>at 3 months and 1 year post randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leeds Dyspepsia Questionnaire</measure>
    <time_frame>at 3 months and 1 year post randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parkinson Disease Questionnaire (PDQ-39)</measure>
    <time_frame>at 3 months and 1 year post randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPDRS Part I</measure>
    <time_frame>at 3 months and 1 year post randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPDRS Part II</measure>
    <time_frame>at 3 months and 1 year post randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPDRS Part IV</measure>
    <time_frame>at 3 months and 1 year post randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment Score</measure>
    <time_frame>at 3 months and 1 year post randomisation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Helicobacter pylori eradication therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amoxycillin 1gm twice a day (BD) Clarithromycin 500mg BD Omeprazole 20mg BD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Maltodextrin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Helicobacter pylori eradication therapy</intervention_name>
    <arm_group_label>Helicobacter pylori eradication therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged â‰¥18 years

          2. Provision of written informed consent

          3. Clinical diagnosis of Parkinson's Disease (PD) assigned by a consultant neurologist

        Exclusion Criteria:

          1. History of previous gastric or major abdominal/pelvic surgery

          2. History of previous eradication therapy for Helicobacter pylori

          3. Antibiotic use in the preceding four weeks or use of anti-acid/prokinetics/laxatives
             in the preceding one week prior to breath test

          4. Recent initiation of dopaminergic medications (within the last three months) or recent
             adjustment of dopaminergic medications (within the last one month)

          5. History of functional neurosurgery for PD

          6. No concomitant neurologic disease except PD

          7. Medical condition that prevents reliable completion of questionnaire
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Malaya</name>
      <address>
        <city>Kuala Lumpur</city>
        <state>Wilayah Persekutuan</state>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2014</study_first_submitted>
  <study_first_submitted_qc>April 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2014</study_first_posted>
  <last_update_submitted>December 7, 2017</last_update_submitted>
  <last_update_submitted_qc>December 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's Disease</keyword>
  <keyword>Helicobacter pylori infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

